Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-23T01:52:18.994Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of recombinant factor VIIa for major haemorrhage

Published online by Cambridge University Press:  29 June 2005

R. J. Pugh ,
R. Wenstone ,
V. J. Martlew  and
G. Marx
R. J. Pugh
Affiliation:
Department of Anaesthesia, Royal Liverpool University Hospital, Liverpool, UK Current address: Department of Anaesthesia, Countess of Chester Hospital, NHS Foundation Trust, Cheshire, UK
R. Wenstone
Affiliation:
Directorate of Intensive Care, Royal Liverpool University Hospital, Liverpool, UK
V. J. Martlew
Affiliation:
Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK
G. Marx
Affiliation:
Department of Anaesthesia, University of Liverpool, Liverpool, UK Current address: Ltd. OA Intensivetherapie, Klinik f. Anästhesiologie und Intensivtherapie, Klinikum der Friedrich-Schiller-Universität Jena, Jena, Germany
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Information
European Journal of Anaesthesiology , Volume 22 , Issue 7 , July 2005 , pp. 548 - 550
Copyright
© 2005 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Rossaint R, Boffard KD, Warren BL et al. Decreased transfusion utilization using recombinant factor VIIa as an adjunct in trauma. Intens Care Med 2004; 30 (Suppl 1): S199.Google Scholar
Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrin 2000; 11 (Suppl 1): S107–S111.Google Scholar
Aggarwal A, Malkovska V, Catlett JP, Alcorn K. Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage. Thromb J 2004; 2: 9.Google Scholar
Clark AD, Gordon WC, Walker ID, Tait RC. ‘Last-ditch’ use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 2004; 86: 120–124.Google Scholar
Meng ZH, Wolberg AS, Monroe III DM, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55: 886–891.Google Scholar
Gallistl S, Cvirn G, Muntean W. Recombinant factor VIIa does not induce hypercoagulability in vitro. Thromb Haemost 1999; 81: 245–249.Google Scholar
Siegel LJ, Gerigk L, Tuttenberg J, Dempfle CE, Scharf J, Fiedler F. Cerebral sinus thrombosis in a trauma patient after recombinant activated factor VII infusion. Anesthesiology 2004; 100: 441–443.Google Scholar